Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma 4Breast Neoplasms 4Sarcoma 3Rhabdomyosarcoma 2Ovarian Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Inflammatory Breast Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma 2Teratoma 1Sarcoma, Synovial 1Recurrent Uterine Corpus Sarcoma 1Recurrent Uterine Corpus Carcinoma 1Pancreatic Neoplasms 1Neutropenia 1Neurofibrosarcoma 1Malignant mesenchymal tumor 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Follicular 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Kidney Neoplasms 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

pegfilgrastim 1Taxes 1Platinum 1Paclitaxel 1Granulocyte Colony-Stimulating Factor 1Fulvestrant 1Filgrastim 1Doxorubicin 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Recurrent Uterine Corpus Carcinoma × pegfilgrastim × Clear all
NCT00063999 2021-10-19

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

GOG Foundation

Phase 3 Completed
1,381 enrolled 12 charts
Gynecologic

Recurrent Uterine Corpus Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡